Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene ther... Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunction and sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company was founded in 2020 and is headquartered in London, the United Kingdom. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1 | -4.70588235294 | 2.125 | 2.275 | 1.95 | 1443028 | 2.0330027 | DE |
| 4 | -0.1 | -4.70588235294 | 2.125 | 2.275 | 1.95 | 924895 | 2.07903736 | DE |
| 12 | 0.025 | 1.25 | 2 | 3.06 | 1.9 | 1596542 | 2.34176608 | DE |
| 26 | 0.2 | 10.9589041096 | 1.825 | 3.06 | 1.25 | 2083215 | 2.07592696 | DE |
| 52 | 1.35 | 200 | 0.675 | 3.06 | 0.575 | 4065227 | 1.46110464 | DE |
| 156 | -0.025 | -1.21951219512 | 2.05 | 3.3 | 0.575 | 2130354 | 1.53996742 | DE |
| 260 | -7.225 | -78.1081081081 | 9.25 | 13.25 | 0.575 | 1798795 | 1.98680046 | DE |
indepth05
5分前
JimBoStevens
12分前
Oleblue
15分前
DR_rugby
23分前
galingolin
32分前
Bigstud is here
36分前
chereb19
39分前
trender18
48分前
chereb19
48分前
Henk van vleuten
50分前
Bigstud is here
55分前
raiderz
1時間前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。